Literature DB >> 16291971

Combination therapy: medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy.

Rupesh Raina1, Kalyana C Nandipati, Ashok Agarwal, David Mansour, David C Kaelber, Craig D Zippe.   

Abstract

The objective of our study was to assess the effectiveness of combining medicated urethral system for erection (MUSE) with sildenafil citrate in men unsatisfied with the sildenafil alone. Baseline and follow-up data from 23 patients (mean age, 62.5 +/- 5.23 years) unsatisfied with the use of the sildenafil citrate alone for the treatment of erectile dysfunction following nerve-sparing radical prostatectomy (mean use, 4 attempts/100-mg dose) was obtained. All patients started oral sildenafil citrate more than 6 months after radical prostatectomy. Combination therapy was initiated using 100 mg sildenafil citrate orally 1 hour prior to intercourse. Patients used combination therapy for a minimum of 4 attempts prior to assessment with the Sexual Health Inventory of Men (International Index for Erectile Function-5) and visual analog scale to gauge rigidity (0-100). The effect of therapy on the total International Index for Erectile Function (IIEF) score and penile rigidity score was assessed. Of the 23 patients, 4 (17%) had no improvement with the addition of medicated urethral system for erection and discontinued the drug, while 19 (83%) reported improvement with the penile rigidity and sexual satisfaction. The IIEF scores of these 19 patients showed significant improvements in each sexual domain, and the patients reported that erection was sufficient for vaginal penetration 80% of the time. Rigidity scores on a scale of 0-100 with sildenafil alone averaged 38% (23-53) for men and 46% (26-67) for their partners. With the addition of MUSE, scores increased to 76% for men and 62% for their partners. We conclude that the addition of MUSE to sildenafil improved sexual satisfaction and penile rigidity in patients unsatisfied with sildenafil alone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291971     DOI: 10.2164/jandrol.05035

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  9 in total

1.  Extending the rationale of combination therapy to unresponsive erectile dysfunction.

Authors:  Christopher Reece; Rajeev Kumar; Diedre Nienow; Ajay Nehra
Journal:  Rev Urol       Date:  2007

2.  Penile Rehabilitation Postprostatectomy: Is There a Role for MUSE?

Authors:  Herbert Lepor; Andrew McCullough
Journal:  Rev Urol       Date:  2008

Review 3.  Combination therapy for erectile dysfunction: an update review.

Authors:  Rohit R Dhir; Hao-Cheng Lin; Steven E Canfield; Run Wang
Journal:  Asian J Androl       Date:  2011-03-21       Impact factor: 3.285

4.  Erectile preservation following radical prostatectomy.

Authors:  Robert Segal; Arthur L Burnett
Journal:  Ther Adv Urol       Date:  2011-02

Review 5.  Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management.

Authors:  Kalyana C Nandipati; Rupesh Raina; Ashok Agarwal; Craig D Zippe
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 6.  Intraurethral alprostadil for erectile dysfunction: a review of the literature.

Authors:  Pierre Costa; Axel-Juerg Potempa
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

7.  Oral and non-oral combination therapy for erectile dysfunction.

Authors:  Ajay Nehra
Journal:  Rev Urol       Date:  2007

Review 8.  What is the current role of intracavernosal injection in management of erectile dysfunction?

Authors:  A I El-Sakka
Journal:  Int J Impot Res       Date:  2016-04-14       Impact factor: 2.896

9.  Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study.

Authors:  Pablo Garrido-Abad; Isabel Senra-Bravo; Celeste Manfredi; Esaú Fernández-Pascual; Estefanía Linares-Espinós; Manuel Fernández-Arjona; David Varillas-Delgado; Juan Ignacio Martínez-Salamanca
Journal:  Int J Impot Res       Date:  2021-01-22       Impact factor: 2.408

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.